Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Incesu, RB; Barletta, F; Tappero, S; Morra, S; Garcia, CC; Scheipner, L; Piccinelli, ML; Tian, Z; Saad, F; Shariat, SF; de, Cobelli, O; Ahyai, S; Chun, FKH; Longo, N; Terrone, C; Briganti, A; Tilki, D; Graefen, M; Karakiewicz, PI.
Conditional survival of stage III non-seminoma testis cancer patients.
Urol Oncol. 2023; 41(10):435.e11-435.e18
Doi: 10.1016/j.urolonc.2023.06.005
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Ahyai Sascha
- Scheipner Lukas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: In many primaries other than non-seminoma testis cancer, the risk of death due to cancer decreases with increasing disease-free interval duration after initial diagnosis and treatment. This effect is known as conditional survival and is relatively unexplored in stage III non-seminoma patients, where it may matter most in clinical decision-making. We examined the effect of disease-free interval duration on overall survival in stage III non-seminoma patients. MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results Database (2004-2018), stage III non-seminoma patients were identified. Multivariable Cox regression analyses and conditional survival models were applied. RESULTS: Of 2,092 surgically treated stage III non-seminoma patients, 385 (18%) exhibited good vs. 558 (27%) intermediate vs. 1,149 (55%) poor prognosis. In multivariable Cox regression models, poor prognosis group independently predicted overall mortality (HR 3.3, P < 0.001). In conditional survival analyses based on 36 months' disease-free interval duration, 5-year overall survival estimates were as follows: good prognosis patients 96 vs. 89% at initial diagnosis without accounting for disease-free interval duration (Δ=+7); intermediate prognosis patients 94 vs. 85% at initial diagnosis without accounting for disease-free interval duration (Δ=+9); poor prognosis patients 94 vs. 65% at initial diagnosis without accounting for disease-free interval duration (Δ=+29). CONCLUSIONS: Conditional survival estimates based on 36 months' disease-free interval duration provide a more accurate and more optimistic outlook for stage III non-seminoma patients than predictions defined at initial diagnosis, without accounting for disease-free interval duration.
- Find related publications in this database (Keywords)
- Testis cancer
- Testicular cancer
- Disease-Free survival
- Prognoses
- Cancer mortality
- SEER program